BusinessHealthScienceTechnologyWorld
Trending

Gastric Cancer Drug Market 2020-2026 Analysis, Trends and Industry Forecast | Leading Players – Bristol-Myers Squibb Company , Novartis AG , Eli Lilly and Company , Sanofi S.A , Amgen Inc., Bayer AG, Celgene Corporation

Gastric Cancer Drug Market

In Gastric Cancer Drug Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and charts which eases the understanding of facts and figures. A proficient data and excellent forecasting techniques used in this report are synonymous with accurateness and correctness. Gastric Cancer Drug Market report is a painstaking analysis of existing scenario of the market which covers several market dynamics. The market study of this global Gastric Cancer Drug Market business report takes into consideration market attractiveness analysis where each segment is benchmarked based on its market size, growth rate & general attractiveness.

Get Sample Analysis of Global Market Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gastric-cancer-drug-market

Global gastric cancer drug market is rising gradually to an estimated value of USD 4.37 billion by 2026 registering a substantial CAGR of 9.6% in the forecast period of 2019-2026. This rise in market value can be attributed vulnerable aging population, robust drug pipeline and people adopting unhealthy lifestyle.

Few of the major competitors currently working in the gastric cancer drug market are, Imugene Limited ,  Otsuka Pharmaceuticals Co., Ltd , Immutep , F. Hoffmann-La Roche Ltd ,   Merck KGaA ,  Bristol-Myers Squibb Company , Novartis AG , Eli Lilly and Company , Sanofi S.A , Amgen Inc., Bayer AG, Celgene Corporation, Gilead Sciences, Inc., AstraZeneca, Ipsen Pharma, Takeda Pharmaceutical Company Limited, Samumed, LLC, Arbutus Biopharma, ASLAN Pharmaceuticals  and among others.

Read Complete Details with TOC Here  https://www.databridgemarketresearch.com/toc/?dbmr=global-gastric-cancer-drug-market

Market Definition: Global Gastric Cancer Drug Market

The gastric cancer drug refers to malignant tumors that begin in the lining of the stomach. This gastric cancer tends to develops over many years. It usually goes undiagnosed since it does not cause any early symptoms.

According to the article published in World Cancer Research Fund, it is identified gastric cancer was responsible for fourth most common malignancy occur in men and seventh rank in women. It is estimated that over 1.00 million new cases seen in the 2018. The high rate of incidence cases occurs in the South Korea in year of 2018. Advances in available medication, accelerating demand of novel therapies and increasing number of gastric related cancer are the drivers to the market.

Segmentation: Global Gastric Cancer Drug Market

Gastric Cancer Drug Market : By Type

  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal stromal tumor
  • Carcinoid tumor
  • Others

Gastric Cancer Drug Market : By Drug Type

  • Doxorubicin Hydrochloride
  • Sunitinib
  • Mitomycin
  • Imatinib
  • Fluorouracil
  • Trastuzumab
  • Docetaxel
  • Others

Gastric Cancer Drug Market : By Treatment

  • Medication
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Immunotherapy
  • Surgery

Gastric Cancer Drug Market : By Route of administration

  • Oral
  • Injectable

Gastric Cancer Drug Market : By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Gastric Cancer Drug Market : By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Key Developments in the Market:

  • On February 2019, Taiho Pharmaceutical Co., Ltd as a subsidiary of Otsuka Holdings Co., Ltd received FDA approval for Lonsurf (trifluridine/tipiracil, TAS-102) for the treatment of patient with advanced or metastatic gastric cancer, which was previously administered on first line chemotherapy
  • On September 2017, Merck & Co., Inc. received accelerated approval from FDA for Keytruda (pembrolizumab) for the treatment of patient with locally advanced or metastatic, gastric or gastro-oesophageal junction adenocarcinoma

Reasons to Purchase this Report

Current and future of global gastric cancer drug market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Want Full Report? Enquire Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-gastric-cancer-drug-market

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475
Mail: Corporatesales@databridgemarketresearch.com

Tags
Close